Healthcare Cost and Utilization before and after Diagnosis of Pseudomonas aeruginosa among Patients with Non-Cystic Fibrosis Bronchiectasis in the U.S

Medical Sciences : Open Access Journal
Christopher M BlanchetteDouglas W Mapel

Abstract

Non-cystic fibrosis bronchiectasis (NCFBE) is a rare, chronic lung disease characterized by bronchial inflammation and permanent airway dilation. Chronic infections with P. aeruginosa have been linked to higher morbidity and mortality. To understand the impact of P. aeruginosa in NCFBE on health care costs and burden, we assessed healthcare costs and utilization before and after P. aeruginosa diagnosis. Using data from 2007 to 2013 PharMetrics Plus administrative claims, we included patients with ≥2 claims for bronchiectasis and >1 claim for P. aeruginosa; then excluded those with a claim for cystic fibrosis. Patients were indexed at first claim for P. aeruginosa and were required to have >12 months before and after the index P. aeruginosa. The mean differences in utilization and costs were assessed using paired Student's t-tests for statistical significance. Mean total healthcare costs per patient were $36,213 pre-P. aeruginosa diagnosis versus $67,764 post-P. aeruginosa, an increase of 87% (p < 0.0001). Inpatient costs represented the largest proportion of total healthcare costs post-P. aeruginosa (54%) with an increase of four hospitalizations per patient (p < 0.0001). NCFBE patients with evidence of P. aeruginosa incur subs...Continue Reading

References

Aug 1, 1996·The European Respiratory Journal·S A EvansM A Woodhead
Aug 1, 1997·The European Respiratory Journal·C B WilsonR Wilson
Feb 7, 1998·Medical Care·A ElixhauserR M Coffey
Oct 30, 2003·The Cochrane Database of Systematic Reviews·D J EvansM Greenstone
Aug 11, 2006·The European Respiratory Journal·G DaviesR Wilson
May 1, 2007·Respiratory Medicine·Paul T KingPeter W Holmes
Oct 10, 2008·Chest·Anne E O'Donnell
Nov 15, 2008·Archivos de bronconeumología·Montserrat VendrellAmparo Solé
Apr 10, 2009·The European Respiratory Journal·M R LoebingerR Wilson
Jul 22, 2010·Thorax·M C PasteurUNKNOWN British Thoracic Society Bronchiectasis non-CF Guideline Group
Aug 10, 2010·Paediatric Respiratory Reviews·Bridget StuartPeter J Mogayzel
Jun 17, 2011·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·T PresslerV Vavrova
Jun 30, 2012·American Journal of Respiratory and Critical Care Medicine·James D ChalmersAdam T Hill
Jan 26, 2013·American Journal of Respiratory and Critical Care Medicine·Michael M TunneyJ Stuart Elborn
Apr 13, 2013·Applied Health Economics and Health Policy·Vijay N JoishSusan Boklage
Aug 1, 2013·American Journal of Respiratory and Critical Care Medicine·Pamela J McShaneMary E Strek
Dec 18, 2013·American Journal of Respiratory and Critical Care Medicine·James D ChalmersAdam T Hill
Jan 22, 2014·Respiratory Medicine·P C GoeminneL J Dupont
Mar 7, 2014·Annals of the American Thoracic Society·Geraint B RogersDavid J Serisier
Nov 19, 2014·PloS One·Wei-jie GuanNan-shan Zhong
Aug 6, 2016·Respiratory Medicine·Robert WilsonEva Polverino
Apr 26, 2017·The Cochrane Database of Systematic Reviews·Simon C Langton Hewer, Alan R Smyth
May 31, 2017·Chronic Respiratory Disease·Derek WeyckerFrederic D Seifer

❮ Previous
Next ❯

Citations

May 29, 2018·Expert Review of Respiratory Medicine·Rodrigo AthanazioMiguel Ángel Martínez-García

❮ Previous
Next ❯

Software Mentioned

PharMetrics
SAS

Related Concepts

Related Feeds

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.